Patents Assigned to Aventis Pasteur
-
Patent number: 6544527Abstract: Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene product and eliminate RNase H activity of the pol gene product through genetic manipulation of the gag and pol genes. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis.Type: GrantFiled: July 9, 1996Date of Patent: April 8, 2003Assignee: Aventis Pasteur LimitedInventors: Benjamin Rovinski, Shi-Xian Cao, Fei-Long Yao, Roy Persson, Michel H. Klein
-
Patent number: 6541250Abstract: The present invention comprises a novel immortal non-adherent human melanocyte cell line, designated WC-1 14.07. This cell line is stable and MHC class I negative. This continuous melanocyte cell line can be used as a source of melanin and hgp100. The Class I MHC-negative nature of this cell line allows it to be used as a target for transfection with MHC class I genes, providing a novel source of hgp100 in a pre-determined MHC context. The cell line can thus be used in a variety of ways, directly or indirectly, in the development and manufacture of vaccines for melanoma.Type: GrantFiled: April 18, 2001Date of Patent: April 1, 2003Assignee: Aventis Pasteur LimitedInventors: Jeannine Alexander, William I. Cox
-
Patent number: 6538123Abstract: The invention concerns a pharmaceutical composition for treating or preventing C hepatitis (HCV), induced infections, which in a preferred embodiment, comprises a main active principle, (i) a fusion polypeptide, including the HCV capsid polypeptide (C191) and polypeptide coat (E1) and in which at least one cleavage site 173/174 and 191/192 has been made inoperative by mutation; (ii) an equimolar mixture of the C191 polypeptide of which the cleavage site 173/174 has been made inoperative and of the E1 polypeptide (mixture equivalent to the fusion polypeptide); or (iii) a DNA molecule coding for this fusion polypeptide. Products (i) to (iii) are characterized in that the C191 element is incapable of regulating the functioning of the genes, in particular of causing them to interact. Such a composition can also include any form equivalent to the products described above.Type: GrantFiled: July 26, 2001Date of Patent: March 25, 2003Assignee: Aventis PasteurInventor: Véronique Barban
-
Patent number: 6521745Abstract: An isolated and purified nucleic acid molecule encoding an inclusion membrane protein C of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae.Type: GrantFiled: August 20, 1999Date of Patent: February 18, 2003Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn, Raymond P. Oomen
-
Patent number: 6518030Abstract: Non-infectious, retrovirus-like particles comprise an assembly of an env gene product, a pol gene product and a gag gene product contain an antigenic marker which is non-retroviral or non-HIV retroviral. In one embodiment, the marker comprises an amino acid sequence containing an epitope inserted into the gag gene product at an antigenically-active insertion site. In another embodiment, the marker comprises an antigenic anchor sequence operatively connected to the env gene product replacing endogenous anchoring function. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis. The presence of the antigenic marker enables recognition that antiserum containing anti-retroviral antibodies has been generated by exposure to the non-infectious retrovirus-like particles by testing for antibodies specific to the antigenic marker.Type: GrantFiled: August 10, 2000Date of Patent: February 11, 2003Assignee: Aventis Pasteur LimitedInventors: Benjamin Rovinski, Shi-Xian Cao, Fei-Long Yao, Roy Persson, Michel H. Klein
-
Patent number: 6503514Abstract: Attenuated strains of Mycobacterium, particularly species of the tuberculosis complex, have the mycobacterial cell entry (mce) gene functionally disabled. The gene may be disabled by an insertion into the gene which disrupts the mycobacterial cell entry function thereof of a selectable marker which is used for screen for homologous recombinants in which a double cross-over event has been effected. The attenuated strains may be used in the immunization of hosts against Mycobacterium disease.Type: GrantFiled: July 7, 2000Date of Patent: January 7, 2003Assignee: Aventis Pasteur LimitedInventors: Bruno Flesselles, Michel H. Klein
-
Patent number: 6486135Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: May 12, 2000Date of Patent: November 26, 2002Assignee: Aventis Pasteur LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6482928Abstract: The crystal structure of the Fab′ fragment of Mab 2F5, a potent neutralizer of both laboratory strains and primary clinical isolates of most clades of HIV-1, both uncompleted and completed with the largely conserved peptide sequence ELDKWAS of the viral envelope protein gp41, has been elucidated and the characteristics of peptide-protein interactions determined. Having regard to such determination, the peptide-mimetics are constrained in the three-dimensional structure to provide an increased immunogenicity to the epitope sequence.Type: GrantFiled: April 13, 1999Date of Patent: November 19, 2002Assignee: Aventis Pasteur Limited and University of TorontoInventors: Emil F. Pai, Michel H. Klein, Pele Chong, Arthur Pedyczak
-
Patent number: 6475780Abstract: A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo.Type: GrantFiled: October 20, 2000Date of Patent: November 5, 2002Assignee: Aventis Pasteur LimitedInventors: Mark Parrington, Xiaomao Li, Michel H. Klein
-
Patent number: 6472159Abstract: The present invention provides a method of inducing an immune response to a subunit antigen in a non-responding subject by administering to the subject a composition comprising the subunit antigen and an amphipathic compound. A preferred antigen is a hepatitis B antigen, and a preferred amphipathic compound is DC-chol.Type: GrantFiled: April 16, 2001Date of Patent: October 29, 2002Assignee: Aventis Pasteur S.A.Inventors: Anne Darbouret, Florence Brunel, Jorge Ronco
-
Patent number: 6471996Abstract: Copolymers designed for use as particulate carriers containing functionalizable amino acid subunits for coupling with targeting ligand are described. The copolymers are polyesters composed of &agr;-hydroxy acid subunits such as D,L-lactide and &agr;-amino acid subunits such as serine or in the preferred embodiment, terpolymers of D,L-lactide and glycolide and &agr;-amino acid subunits such as serine. Stable vaccine preparations useful as delayed release formulations containing antigen(s) or antigen(s) and co-adjuvants encapsulated within or physically mixed with polymeric microparticles are described. The particulate carriers are useful for delivering agents to the immune system of a subject by mucosal or parenteral routes to produce immune responses, including antibody responses.Type: GrantFiled: February 11, 2000Date of Patent: October 29, 2002Assignee: Aventis Pasteur LimitedInventors: Kenneth K. Sokoll, Pele Chong, Michel H. Klein
-
Patent number: 6472506Abstract: The invention relates to a polysaccharide-peptide conjugate wherein the polysaccharide is advantageously immunogenic, which comprises a polysaccharide chain composed of repeat units and a plurality of peptide moieties, each moiety containing a cysteine residue and being covalently attached at random along the polysaccharide chain, through an indirect bond being achieved through either a linker or a spacer-linker moiety provided that the spacer entity of the spacer-linker moiety is linked to the amino, hydroxyl or carboxyl group of the polysaccharide. To this end a useful linker may be, e.g., N-(&ggr;-maleimidobutyrloxy)succinimide ester. Such a conjugate may typically exhibit a “Rake” configuration. Conjugation processes are also disclosed. Conjugates of the invention are in particular useful in the vaccinal field to elicit a protective long term immune response against a pathogenic microorganism from which the Immunogenic polysaccharide is derived.Type: GrantFiled: November 4, 1998Date of Patent: October 29, 2002Assignee: Aventis Pasteur S.A.Inventors: Monique Moreau, Noëlle Mistretta
-
Patent number: 6465171Abstract: The present invention relates to the detection of the presence of reverse transcriptase enzymatic activity in eukaryotic cell lines. Specifically, the present invention comprises a method for discriminating between endogenous reverse transcriptase activity in a substrate cell line (e.g., avian) used as substrates for the manufacture of biological products (including viral vaccines) from exogenous infectious retrovirus by using a combination of transmissibility assay (viral replication) and PBRT assay (RT-PCR). Appropriate levels of viral amplification and number of PCR cycles are determined and employed that permit detection of exogenous infectious RT activity but not endogenous RT activity.Type: GrantFiled: June 14, 2000Date of Patent: October 15, 2002Assignee: Aventis PasteurInventors: Scott Goebel, Maurice Harmon, Jim Tartaglia, William Lapps, Francois Pelloquin, Dennis W. Trent
-
Patent number: 6464979Abstract: Immunogenic compositions including vaccines are described that comprise an outer membrane antigen extract of a strain of Chlamydia and are effective in protection against disease caused by Chlamydia infection. The immunogenic compositions may comprise the major outer membrane protein (MOMP) of Chlamydia which may be in a homooligomeric form or complexed with at least one other antigen of Chlamydia. The immunogenic composition may include an immunostimulating complex (ISCOM) and the outer membrane antigen may be incorporated therein. The immunogenic compositions have utility as chlamydial vaccines and in diagnostic applications.Type: GrantFiled: September 12, 1996Date of Patent: October 15, 2002Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Brian J. Underdown
-
Patent number: 6455050Abstract: Immunogenic envelope glycoproteins are produced from enveloped virus, such as of the paramyxoviridae family, particularly PIV-3 and RSV, by culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from the tissue culture, solubilizing the envelope glycoproteins and isolating the solubilized envelope glycoproteins by chromatography.Type: GrantFiled: April 26, 1995Date of Patent: September 24, 2002Assignee: Aventis Pasteur LimitedInventors: Mary Elizabeth Ewasyshyn, Barry Ian Caplan, Anne-Marie Bonneau, Michel Henri Klein
-
Patent number: 6451322Abstract: Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene, product and eliminate RNase H activity of the pol gene product through genetic manipulation of the gag and pol genes. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis.Type: GrantFiled: February 26, 1999Date of Patent: September 17, 2002Assignee: Aventis Pasteur LimitedInventors: Benjamin Rovinski, Shi-Xian Cao, Fei-Long Yao, Roy Persson, Michel H. Klein
-
Patent number: 6448386Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.Type: GrantFiled: March 19, 1998Date of Patent: September 10, 2002Assignee: Aventis Pasteur LimitedInventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Pele Chong, Michel H. Klein
-
Patent number: 6444444Abstract: A gene from a strain of Mycobacterium encoding a protein of molecular weight between about 45 to about 60 kDa and associated with cell binding and cell entry was cloned. The genes and encoded protein have utility in immunogenic preparations or diagnostic applications.Type: GrantFiled: July 10, 1996Date of Patent: September 3, 2002Assignee: Aventis Pasteur LimitedInventors: Naveen N. Anand, Michel H. Klein
-
Patent number: 6440424Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, has a molecular mass of about 200 kDa. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.Type: GrantFiled: June 7, 1995Date of Patent: August 27, 2002Assignee: Aventis Pasteur LimitedInventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Michel H. Klein
-
Patent number: 6440425Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.Type: GrantFiled: March 26, 1996Date of Patent: August 27, 2002Assignee: Aventis Pasteur LimitedInventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Pele Chong, Michel H. Klein